Press Releases

Press Releases

June 16, 2020
– Proceeds will be used to advance 4DMT’s three precision-guided AAV gene therapy candidates through initial clinical proof-of-concept, to advance pre-clinical product pipeline and proprietary next-generation Therapeutic Vector Evolution platform, and to expand internal GMP manufacturing
December 6, 2018
Emeryville, CA – December 6, 2018  – 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced a research and development collaboration with the Casey Eye Institute (CEI)
November 6, 2018
Emeryville, CA – November 6, 2018  – 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced that company management will participate at the following upcoming investor